Health
British Columbia reimburses FRUZAQLATM (fruquintinib capsules) for the treatment of metastatic colorectal cancer (mCRC)
Takeda Canada Inc. ("Takeda") is pleased to announce that FRUZAQLATM (fruquintinib capsules) will now be reimbursed by BC Cancer as a treatment option for adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with, or are not considered candidates, for available standard therapies.[1] This treatment is available to patients under certain criteria.
About this update from Takeda Pharmaceutical Co. Ltd.
[{"type":"text","content":"TORONTO, Dec. 16, 2025 /CNW/ - Takeda Canada Inc. ("Takeda") is pleased to announce that FRUZAQLATM (fruquintinib capsules) will now be reimbursed by BC Cancer as a treatment option for adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with, or are not considered candidates, for available standard therapies.[1] This treatment is available to patients under certain criteria.","length":425,"tagName":"p"},{"type":"image","alt":"Takeda Canada (CNW Group/Takeda Canada Inc.)","displaySize":"","headline":null,"caption":"Takeda Canada (CNW Group/Takeda Canada Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":210,"url":"https://media.zenfs.com/en/cnwgroup.com/57e50e31b28cdae79dc511a1359f9651"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/lYOfi0DrUbGzV2ukHitIeg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTM3MDtjZj13ZWJw/https://media.zenfs.com/en/cnwgroup.com/57e50e31b28cdae79dc511a1359f9651","width":400,"height":210}},"href":"https://mma.prnewswire.com/media/2845834/Takeda_Canada_Inc__British_Columbia_reimburses%C2%A0FRUZAQLATM%C2%A0_fruqu.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""Colorectal cancer remains the second leading cause of cancer-related deaths in Canada. For patients with advanced disease, timely access to new and innovative therapies is important," said Barry D. Stein, President and CEO of Colorectal Cancer Canada. "As both an advocate and someone who has lived experience with stage IV colon cancer, I am encouraged to see this new treatment become available. It offers renewed hope for potentially improved outcomes and quality of life for those facing the most challenging stages of this disease."","length":558,"tagName":"p"},{"type":"text","content":"mCRC refers to cancer of the colon that has spread to other parts of the body (called distant metastasis), such as to the liver or lungs.[2] It's estimated that over 3,600 people in British Columbia are diagnosed with colorectal cancer (CRC) every year, with rising rates in young people under age 50.[3] Approximately 70 per cent of patients with CRC will experience metastatic disease, whether at diagnosis or after treatment with metastases being the main cause of CRC-related death.[4],[5]","length":507,"tagName":"p"},{"type":"text"...